These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28110541)

  • 1. Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population.
    Ding P; Wei Y; Chen N; Liu H
    Clin Appl Thromb Hemost; 2018 Apr; 24(3):452-461. PubMed ID: 28110541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein phosphorylation to assess P2Y12 -inhibition after ticagrelor intake.
    Hobl EL; Jilma B; Derhaschnig U; Schoergenhofer C; Schwameis M; Jilma-Stohlawetz P
    Cytometry B Clin Cytom; 2015; 88(6):385-8. PubMed ID: 24038908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
    Abtan J; Silvain J; Kerneis M; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Collet JP; Montalescot G
    Thromb Haemost; 2013 Nov; 110(5):1055-64. PubMed ID: 23925438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
    Danese E; Fava C; Beltrame F; Tavella D; Calabria S; Benati M; Gelati M; Gottardo R; Tagliaro F; Guidi GC; Cattaneo M; Minuz P
    J Thromb Haemost; 2016 Feb; 14(2):282-93. PubMed ID: 26576037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition.
    Jakubowski JA; Bourguet N; Boulay-Moine D; Sugidachi A; Yamaguchi S; Barragan P; Zhou C; Moulard M
    Thromb Haemost; 2012 Feb; 107(2):388-95. PubMed ID: 22186965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
    Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
    Thromb Haemost; 2013 Oct; 110(4):769-76. PubMed ID: 23903326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.
    Kuliczkowski W; Rychlik B; Chiżyński K; Watała C; Golański J
    Pol Arch Med Wewn; 2011 Apr; 121(4):115-21. PubMed ID: 21532533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.
    Kim IS; Jeong YH; Tantry US; Park Y; Lee DH; Bliden KP; Koh JS; Park JR; Jang JS; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S; Gurbel PA
    Am Heart J; 2013 Jul; 166(1):95-103. PubMed ID: 23816027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.
    Aleil B; Ravanat C; Cazenave JP; Rochoux G; Heitz A; Gachet C
    J Thromb Haemost; 2005 Jan; 3(1):85-92. PubMed ID: 15634270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y
    Hobl EL; Jilma B; Derhaschnig U; Schoergenhofer C; Schwameis M; Jilma-Stohlawetz P
    Cytometry B Clin Cytom; 2013 Jul; ():. PubMed ID: 23897720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
    JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ticagrelor and clopidogrel on platelet aggregation function after percutaneous coronary intervention in patients with acute coronary syndrome.
    Sui Z; Qu P
    J Biol Regul Homeost Agents; 2019 Mar-Apr,; 33(2):439-445. PubMed ID: 30971068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Modified Impedance Whole Blood Platelet Aggregation Method Detecting Platelet Function in ACS Patients with Different CYP2C19 Genotypes.
    Cui C; Qiao R; Zhang J
    Clin Lab; 2016; 62(1-2):13-20. PubMed ID: 27012029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.
    Bonello L; Paganelli F; Arpin-Bornet M; Auquier P; Sampol J; Dignat-George F; Barragan P; Camoin-Jau L
    J Thromb Haemost; 2007 Aug; 5(8):1630-6. PubMed ID: 17488353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
    Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
    Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.